Clinical translation of tissue-engineered advanced therapeutic medicinal products is hindered by a lack of patient-dependent and independent in-process biological quality controls that are reflective of in vivo outcom...Clinical translation of tissue-engineered advanced therapeutic medicinal products is hindered by a lack of patient-dependent and independent in-process biological quality controls that are reflective of in vivo outcomes.Recent insights into the mechanism of native bone repair highlight a robust path dependence.Organoid-based bottom-up developmental engineering mimics this pathdependence to design personalized living implants scaffold-free,with in-build outcome predictability.Yet,adequate(noninvasive)quality metrics of engineered tissues are lacking.Moreover,insufficient insight into the role of donor variability and biological sex as influencing factors for the mechanism toward bone repair hinders the implementation of such protocols for personalized bone implants.Here,male and female bone-forming organoids were compared to non-bone-forming organoids regarding their extracellular matrix composition,transcriptome,and secreted proteome signatures to directly link in vivo outcomes to quality metrics.As a result,donor variability in bone-forming callus organoids pointed towards two distinct pathways to bone,through either a hypertrophic cartilage or a fibrocartilaginous template.The followed pathway was determined early,as a biological sexdependent activation of distinct progenitor populations.Independent of donor or biological sex,a cartilage-to-bone transition was driven by a common panel of secreted factors that played a role in extracellular matrix remodeling,mineralization,and attraction of vasculature.Hence,the secreted proteome is a source of noninvasive biomarkers that report on biological potency and could be the missing link toward data-driven decision-making in organoid-based bone tissue engineering.展开更多
基金financed by the Hercules Foundation(project AKUL/13/47)funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 874837+2 种基金supported by the Flemish Government(department of Economy,Science and Innovation)through the Regenerative Medicine Crossing Borders(http://www.regmedxb.com)initiativeImages were recorded on a Zeiss LSM 780-SP Mai Tai HP DS(Cell and Tissue Imaging Cluster(CIC),Supported by Hercules AKUL/11/37 and FWO G.0929.15 to Pieter Vanden Berghe,University of Leuvensupported by Interne Fondsen KU Leuven/Internal Funds KU Leuven grant numbers C24M/22/058.
文摘Clinical translation of tissue-engineered advanced therapeutic medicinal products is hindered by a lack of patient-dependent and independent in-process biological quality controls that are reflective of in vivo outcomes.Recent insights into the mechanism of native bone repair highlight a robust path dependence.Organoid-based bottom-up developmental engineering mimics this pathdependence to design personalized living implants scaffold-free,with in-build outcome predictability.Yet,adequate(noninvasive)quality metrics of engineered tissues are lacking.Moreover,insufficient insight into the role of donor variability and biological sex as influencing factors for the mechanism toward bone repair hinders the implementation of such protocols for personalized bone implants.Here,male and female bone-forming organoids were compared to non-bone-forming organoids regarding their extracellular matrix composition,transcriptome,and secreted proteome signatures to directly link in vivo outcomes to quality metrics.As a result,donor variability in bone-forming callus organoids pointed towards two distinct pathways to bone,through either a hypertrophic cartilage or a fibrocartilaginous template.The followed pathway was determined early,as a biological sexdependent activation of distinct progenitor populations.Independent of donor or biological sex,a cartilage-to-bone transition was driven by a common panel of secreted factors that played a role in extracellular matrix remodeling,mineralization,and attraction of vasculature.Hence,the secreted proteome is a source of noninvasive biomarkers that report on biological potency and could be the missing link toward data-driven decision-making in organoid-based bone tissue engineering.
